Over the past 16 years we have built a solid foundation for future growth. Our reputation for quality, and strong track record of success support our plan for accelerated growth in 2021 and years beyond.
Everest’s growth is accelerating. We have grown steadily and organically for the past 16 years and have focused on delivering with quality, providing exceptional customer services as well as the flexibility in order to meet clients’ timelines and specific requirements. We systematically built our foundations by bringing on and developing a large and capable management team, developing robust processes and tools, and a “can-do” culture across all levels of our employee base. We expanded our services and capabilities, growing from our deep roots in clinical data management and biostatistics and statistical programming, to becoming a data and information driven, quality focused full service Clinical Research Organization (CRO). We will continue to build and innovate upon our offerings to serve all of our client’s unique needs. We have diversified geographically with offices established in strategic locations to better serve our clients and access to high quality talent pools. With all our investments to date, we have been experiencing increased demands for our services, and we are ready for an accelerated next phase development and growth.
Arlington Capital Partners has made a majority investment in Everest alongside Everest’s founding shareholders and senior management who will continue to lead the Company. In November 2020, Everest embarks upon this next phase of growth with a new strategic partnership with Arlington Capital Partners (“Arlington”), a Washington, DC-based private equity firm. We have chosen to partner with Arlington because of its long track record of success investing in and scaling healthcare businesses, its deep expertise in the pharmaceutical services sector, and its reputation for partnering with founder-owned and operated businesses. We are extremely pleased to work together with Arlington as they share our vision for expanding Everest’s capabilities to better serve our customers while at the same time maintaining our unique culture. Arlington’s ability to provide significant strategic and financial support will further enable Everest to expand our service lines, grow our employee base, and most importantly, provide best-in-class support to our customers throughout the lifecycle of their clinical trials.
Arlington is currently investing out of Arlington Capital Partners V, L.P., a $1.7 billion fund. The firm has managed approximately $4.0 billion of committed capital via five investment funds. Arlington is focused on middle market investment opportunities in growth industries including healthcare, government services and technology, aerospace & defense, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their Company’s position as leading competitors in their field. www.arlingtoncap.com.
Everest’s leadership team will not change. While Arlington will provide significant strategic and financial support to grow the Everest business and further strengthen its platform for accelerated growth, they value the strength of our Leadership team who will be instrumental to supporting Everest’s growth over the next five years. The new partnership will not result in changes to Everest’s Leadership team or our existing employee base, in fact, Everest will be better capitalized to broaden our capacity and reach to serve our rapidly expanding pipeline of existing and new clients. The Everest Leadership team is excited for this next phase of Everest’s growth journey and look forward to the unique opportunities ahead.
With growth, comes entrepreneurial and career building opportunities for Everest employees across all levels. We will continue to innovate, build, and invest in developing the technical and leadership skills of our people. We will continue to expand the capacity of our high quality delivery teams as we enrich our existing offerings, build new service and operational capabilities, enter into new frontiers, win new projects and clients, and continue to build our reputation in the industry as a CRO centre of excellence!